Table 2.
Recurrence and reirradiation characteristics
| n | % | ||
|---|---|---|---|
| Time to first recurrence, months | Median (range) | 11.8 (3.0–191.5) | |
| Time from diagnosis to reRT, months | Median (range) | 20.9 (4.2–277.9) | |
| Number of recurrences before reRT | 1 | 6 | 13% |
| 2 | 11 | 23% | |
| 3 | 15 | 31% | |
| 4 | 9 | 19% | |
| 5 | 7 | 15% | |
| Prior salvage chemotherapy | Yes | 42 | 88% |
| No | 6 | 13% | |
| Salvage chemotherapy agents | Bevacizumab | 36 | 86% |
| Lomustine | 27 | 64% | |
| TMZ | 26 | 62% | |
| Dasatinib | 4 | 10% | |
| Carmustine | 2 | 5% | |
| Procarbazine | 2 | 5% | |
| PCV | 2 | 5% | |
| Irinotecan | 1 | 2% | |
| Etoposide | 1 | 2% | |
| TRC105 | 1 | 2% | |
| Prior salvage surgery | None | 27 | 56% |
| 1 | 17 | 35% | |
| 2 | 4 | 8% | |
| Type of salvage surgeryA | Biopsy | 2 | 8% |
| GTR | 13 | 52% | |
| STR | 10 | 40% | |
| Chemotherapy with reRT | None | 15 | 31% |
| Bevacizumab | 23 | 48% | |
| Bevacizumab + lomustine | 2 | 4% | |
| Bevacizumab + TMZ | 2 | 4% | |
| TMZ | 6 | 13% | |
| Reirradiation dose (Gy) / fractions | 28 Gy / 5 fx | 1 | 2% |
| 30 Gy / 5 fx | 1 | 2% | |
| 30 Gy / 6 fx | 1 | 2% | |
| 31.5 Gy / 9 fx | 2 | 4% | |
| 33 Gy / 9 fx | 1 | 2% | |
| 35 Gy / 10 fx | 23 | 48% | |
| 40 Gy / 10 fx | 12 | 25% | |
| 40 Gy / 15 fx | 4 | 8% | |
| 45 Gy / 10 fx | 1 | 2% | |
| 50 Gy / 25 fx | 1 | 2% | |
| 60 Gy / 30 fx | 1 | 2% | |
| Reirradiation PTV volume (cm3) | Median (range) | 49 (3–265) | |
reRT: reirradiation, TMZ: temozolomide, PCV: procarbazine, lomustine, vincristine, GTR: gross total resection, STR: subtotal resection, PTV: planning target volume.
Abecause 25 surgical procedures took place in 21 patients, the denominator is 25.